Blog
Breast tumor markers: modern laboratory navigation in oncology
Breast cancer is one of the most common types of malignant tumors among women in the world. And although ultrasound, mammography and MRI remain the main diagnostic methods, it is tumor markers that open a new level of understanding of the course of the disease. Thanks to laboratory tests, it is possible not only to detect relapses at an early stage, but also to personalize treatment, assess the aggressiveness of the tumor and adapt therapy to the biological characteristics of the body.
These markers are not substitutes for instrumental studies, but they can make the medical picture much more accurate.
Breast cancer markers are substances produced by tumor cells or healthy cells in response to the oncological process. Some of them circulate in the blood, others are studied only in tissue samples. The level of these indicators helps doctors:
determine the probability of a malignant process
evaluate the effectiveness of treatment
monitor remission
predict the course of the disease
CA 15-3 is the most common blood marker for breast cancer
This marker is most often used to monitor the course of the disease. It is elevated in women with invasive breast cancer, especially when it has spread to the bones, liver, or lungs. Its levels do not always change in the early stages, so CA 15-3 is not effective for screening. However, it allows you to assess the dynamics during chemotherapy or hormone therapy.
It is worth knowing that this marker can also be elevated in some benign conditions, such as mastopathy or hepatitis, so it evaluated only in the context of the clinical picture.
CEA is a universal marker that can complement CA 15-3
CEA (carcinoembryonic antigen) is nonspecific but may be useful in monitoring tumor progression. Its levels are often elevated in metastatic disease, especially in the lung. It may also be elevated in smokers, even without a tumor.
The combined determination of CA 15-3 and CEA allows you to increase the sensitivity of monitoring and respond to changes in a timely manner.
HER2/neu — a biomarker for targeted therapy
Unlike the previous ones, HER2 is not examined in the blood, but is determined in the tumor tissue. This is a protein responsible for cell growth. Its overexpression is characteristic of aggressive forms of cancer. HER2-positive tumors require a special approach to treatment - using targeted drugs (trastuzumab, pertuzumab).
Knowing HER2 status is critical for choosing the right therapeutic strategy.
Hormone receptors: estrogen (ER) and progesterone (PR)
These markers allow you to determine whether the tumor is dependent on hormonal influences. If the receptors are positive, hormone therapy is prescribed (tamoxifen, aromatase inhibitors). Determination of ER and PR is mandatory when making a diagnosis, because the prognosis for survival and the risk of recurrence depend on them.
Ki-67 proliferation index — an assessment of tumor growth rate
It is a marker of the rate of cell division. High Ki-67 indicates a rapidly growing tumor that requires more aggressive treatment. Its value helps to differentiate the tumor type (e.g., luminal A or B) and to form an individual protocol.
Key table: tumor markers and their role in breast cancer
| Tumor marker | How is it determined? | What is it used for? |
|---|---|---|
| CA 15-3 | Blood | Monitoring treatment and relapses |
| CEA | Blood | Assessment of spread and presence of metastases |
| HER2/neu | Cloth | Definition of targeted therapy |
| ER, PR | Cloth | Prognosis and choice of hormone therapy |
| Ki-67 | Cloth | Assessment of tumor aggressiveness |
When is it appropriate to take breast cancer markers?
After diagnosis — to assess tumor biology
During chemotherapy or hormonal treatment - to assess effectiveness
After the end of treatment - for relapse monitoring
If new symptoms appear - bone pain, weakness, changes in blood or ultrasound
When planning personalized therapy
Tumor markers are not used for self-diagnosis or screening. But in the hands of an experienced oncologist, they become a powerful tool for managing the disease at all stages.
Breast tumor markers are not a universal “cancer test”, but they are extremely valuable information for accurate disease management. Their correct interpretation helps not only to diagnose or control the disease, but also to avoid over- or undertreatment. And most importantly, to save the patient’s life, time and resources.
